Tuyển tập các báo cáo nghiên cứu về hóa học được đăng trên tạp chí sinh học quốc tế đề tài : Biocompatibility of Poly-ε-caprolactone-hydroxyapatite composite on mouse bone marrow-derived osteoblasts and endothelial cells | Journal of Orthopaedic Surgery and Research BioMed Central Open Access Research article Biocompatibility of Poly-e-caprolactone-hydroxyapatite composite on mouse bone marrow-derived osteoblasts and endothelial cells Haiying Yu1 2 Paul H Wooley1 2 and Shang-You Yang 1 2 3 Address Department of Biomedical Engineering Wayne State University Detroit Michigan USA 2Department of Orthopaedic Surgery Wayne State University Detroit Michigan USA and 3Orthopaedic Research Institute Via Christi Health System Department of Biological Sciences Wichita State University 1845 Fairmount Street Wichita KS 67260 USA Email Haiying Yu - gemofseayhy@ Paul H Wooley - Paul_Wooley@ Shang-You Yang - Corresponding author Published 26 February 2009 Received 17 May 2008 Journal of Orthopaedic Surgery and Research 2009 4 5 doi I749-799X-4-5 Accepted 26 February 2009 This article is available from http content 4 1 5 2009 Yu et al licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract Background Tissue-engineered bone may be developed by seeding the cells capable of both osteogenesis and vascularization on biocompatible composite scaffolds. The current study investigated the performance of mice bone marrow-derived osteogenic cells and endothelial cells as seeded on hydroxyapatite HA and poly-e-caprolactone PCL composite scaffolds. Methods Mononuclear cells were induced to osteoblasts and endothelial cells respectively which were defined by the expression of osteocalcin alkaline phosphatase ALP and deposits of calcium-containing crystal for osteoblasts or by the expression of vascular endothelial growth factor receptor-2 VEGFR-2 and von Willebrand factor vWF and the formation .
